 |
|
|
| |
Tenofovir disoproxil fumarate and tenofovir alafenamide interruption in hepatitis B and human immunodeficiency virus co-infected individuals in the United States: monitoring practices and incidence of hepatitis B reactivation or hepatitis flare
|
| |
| |
EASL 2024 June 5-8 Milan Italy
Douglas T. Dieterich1, Laurence Brunet2, Ricky Hsu3,4, Karam Mounzer5, Gerald Pierone6, Michael Wohlfeiler7, Jennifer Fusco2, Megan Dunbar8, Joshua Gruber8, Leland J. Yee8, Catherine Frenette8, Gregory Fusco2. 1Icahn School of Medicine at Mount Sinai, New York, United States; 2Epividian, Raleigh, United States; 3AIDS Healthcare Foundation, New York, United States; 4NYU Langone Medical Center, New York, United States; 5Philadelphia FIGHT, Philadelphia, United States; 6Whole Family Health Center, Vero Beach, United States; 7AIDS Healthcare Foundation, Miami, United States; 8Gilead Sciences, Inc., Foster City, United States
|
| |
|
|
|
|
|
